About Kuros Biosciences AG (CSBTF) — Dividend Analysis 2026
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
Is CSBTF a good dividend investment in 2026?
CSBTF offers a 7.18% forward yield with a 50% payout ratio. Strand Safety Score: 60/100 (Moderate Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
CSBTF DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your CSBTF portfolio grows to $10.99M vs $10.25M without reinvestment. This is the compound interest effect in action.
CSBTF dividend growth history & forecast
CSBTF has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 7.18%.
Company generates negative FCF ($-2M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
30 / 30 pts
30/30
Debt/EBITDA 0.0× — low leverage, balance sheet is strong
Earnings Momentum+0.0B → -0.0B → -0.0B
30 / 30 pts
30/30
Net income grew for 2 consecutive years — strong earnings momentum
OVERALL ASSESSMENT
Dividend at moderate risk — monitor coverage and debt closely.
STRAND SCORE
60
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 CSBTF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CSBTF.
Gross yield
7.18%
Tax rate
15.00%
After-tax yield
6.10%
Real yield (−CPI)
3.30%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
7.18%
4.38%
$718 / yr
🇺🇸 US Taxable (15%) ✓
15%
6.10%
3.30%
$610 / yr
🇺🇸 US Taxable (20%)
20%
5.74%
2.94%
$574 / yr
🇬🇧 UK ISA
0%
7.18%
4.38%
$718 / yr
🇬🇧 UK Taxable
8.75%
6.55%
3.75%
$655 / yr
🇨🇦 TFSA
0%
7.18%
4.38%
$718 / yr
🇨🇦 CA Taxable
25%
5.38%
2.58%
$539 / yr
🇦🇺 Super (pension)
15%
6.10%
3.30%
$610 / yr
🇦🇺 AU Taxable
30%
5.03%
2.23%
$503 / yr
🇩🇪 DE Taxable
26.375%
5.29%
2.49%
$529 / yr
🇫🇷 FR Taxable
30%
5.03%
2.23%
$503 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CSBTF Income Goal & Break-Even
Dividend Break-Even
17yr
Years for dividends to fully repay your CSBTF investment of $27.85/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$6.4K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$3.9K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in CSBTF for:
Shares needed
14,118
Capital required
$393,186
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CSBTF Dividend Payment Schedule
CSBTF pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 CSBTF vs Healthcare Benchmarks
How CSBTF compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+4.38% vs sectorBetter
CSBTF
7.18%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
CSBTF
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
CSBTF
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CSBTF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CSBTF Insider Activity
No recent SEC filings reported in the last 90 days.
📅
Next Earnings Report: 2026-08-13(in 135 days)
🔬
Financial Health Scores
Altman Z-Score
14.99
✅ Safe Zone — low bankruptcy risk
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
4/9
⚠️ Moderate fundamentals
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CSBTF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →